Forskning ved Københavns Universitet - Københavns Universitet

Forside

Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation. / Kornblit, Brian; Masmas, Tania; Petersen, Søren L; Madsen, Hans O; Heilmann, Carsten; Schejbel, Lone; Sengeløv, Henrik; Müller, Klaus; Garred, Peter; Vindeløv, Lars; Kornblit, Brian Thomas; Masmas, Tania; Petersen, Søren; Madsen, Hans O; Heilmann, Carsten; Schejbel, Lone; Sengeløv, Henrik; Müller, Klaus; Garred, Peter; Vindeløv, Lars.

I: Biology of Blood and Marrow Transplantation, Bind 16, Nr. 2, 01.02.2010, s. 239-52.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Kornblit, B, Masmas, T, Petersen, SL, Madsen, HO, Heilmann, C, Schejbel, L, Sengeløv, H, Müller, K, Garred, P, Vindeløv, L, Kornblit, BT, Masmas, T, Petersen, S, Madsen, HO, Heilmann, C, Schejbel, L, Sengeløv, H, Müller, K, Garred, P & Vindeløv, L 2010, 'Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation', Biology of Blood and Marrow Transplantation, bind 16, nr. 2, s. 239-52. https://doi.org/10.1016/j.bbmt.2009.10.002, https://doi.org/10.1016/j.bbmt.2009.10.002

APA

Kornblit, B., Masmas, T., Petersen, S. L., Madsen, H. O., Heilmann, C., Schejbel, L., Sengeløv, H., Müller, K., Garred, P., Vindeløv, L., Kornblit, B. T., Masmas, T., Petersen, S., Madsen, H. O., Heilmann, C., Schejbel, L., Sengeløv, H., Müller, K., Garred, P., & Vindeløv, L. (2010). Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation, 16(2), 239-52. https://doi.org/10.1016/j.bbmt.2009.10.002, https://doi.org/10.1016/j.bbmt.2009.10.002

Vancouver

Kornblit B, Masmas T, Petersen SL, Madsen HO, Heilmann C, Schejbel L o.a. Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation. 2010 feb 1;16(2):239-52. https://doi.org/10.1016/j.bbmt.2009.10.002, https://doi.org/10.1016/j.bbmt.2009.10.002

Author

Kornblit, Brian ; Masmas, Tania ; Petersen, Søren L ; Madsen, Hans O ; Heilmann, Carsten ; Schejbel, Lone ; Sengeløv, Henrik ; Müller, Klaus ; Garred, Peter ; Vindeløv, Lars ; Kornblit, Brian Thomas ; Masmas, Tania ; Petersen, Søren ; Madsen, Hans O ; Heilmann, Carsten ; Schejbel, Lone ; Sengeløv, Henrik ; Müller, Klaus ; Garred, Peter ; Vindeløv, Lars. / Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation. I: Biology of Blood and Marrow Transplantation. 2010 ; Bind 16, Nr. 2. s. 239-52.

Bibtex

@article{8fe04bb0537311df928f000ea68e967b,
title = "Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation",
abstract = "Several studies have demonstrated that genetic variation in cytokine genes can modulate the immune reactions after allogeneic hematopoietic cell transplantation (HCT). High mobility group box 1 protein (HMBG1) is a pleiotropic cytokine that functions as a pro-inflammatory signal, important for the activation of antigen presenting cells (APCs) and propagation of inflammation. HMGB1 is implicated in the pathophysiology of a variety of inflammatory diseases, and we have recently found the variation in the HMGB1 gene to be associated with mortality in patients with systemic inflammatory response syndrome. To assess the impact of the genetic variation in HMGB1 on outcome after allogeneic HCT, we genotyped 276 and 146 patient/donor pairs treated with allogeneic HCT for hematologic malignancies following myeloablative (MA) or nonmyeloablative (NMA) conditioning. Associations between genotypes and outcome were only observed in the cohort treated with MA conditioning. Patient homozygosity or heterozygosity for the-1377delA minor allele was associated with increased risk of relapse (hazard ratio [HR] 2.11, P = .02) and increased relapse related mortality (RRM) (P = .03). Furthermore, patient homozygosity for the 3814C > G minor allele was associated with increased overall survival (OS; HR 0.13, P = .04), progression free survival (PFS; HR 0.30, P = .05) and decreased probability of RRM (P = .03). Patient carriage of the 2351insT minor allele reduced the risk of grade II to IV acute graft-versus-host disease (aGVHD) (HR 0.60, P = .01), whereas donor homozygosity was associated with chronic GVHD (cGVHD) (HR 1.54, P = .01). Our findings suggest that the inherited variation in HMGB1 is associated with outcome after allogeneic HCT following MA conditioning. None of the polymorphisms were associated with treatment-related mortality (TRM).",
author = "Brian Kornblit and Tania Masmas and Petersen, {S{\o}ren L} and Madsen, {Hans O} and Carsten Heilmann and Lone Schejbel and Henrik Sengel{\o}v and Klaus M{\"u}ller and Peter Garred and Lars Vindel{\o}v and Kornblit, {Brian Thomas} and Tania Masmas and S{\o}ren Petersen and Madsen, {Hans O} and Carsten Heilmann and Lone Schejbel and Henrik Sengel{\o}v and Klaus M{\"u}ller and Peter Garred and Lars Vindel{\o}v",
note = "Copyright 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.",
year = "2010",
month = feb,
day = "1",
doi = "10.1016/j.bbmt.2009.10.002",
language = "English",
volume = "16",
pages = "239--52",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier",
number = "2",

}

RIS

TY - JOUR

T1 - Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation

AU - Kornblit, Brian

AU - Masmas, Tania

AU - Petersen, Søren L

AU - Madsen, Hans O

AU - Heilmann, Carsten

AU - Schejbel, Lone

AU - Sengeløv, Henrik

AU - Müller, Klaus

AU - Garred, Peter

AU - Vindeløv, Lars

AU - Kornblit, Brian Thomas

AU - Masmas, Tania

AU - Petersen, Søren

AU - Madsen, Hans O

AU - Heilmann, Carsten

AU - Schejbel, Lone

AU - Sengeløv, Henrik

AU - Müller, Klaus

AU - Garred, Peter

AU - Vindeløv, Lars

N1 - Copyright 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Several studies have demonstrated that genetic variation in cytokine genes can modulate the immune reactions after allogeneic hematopoietic cell transplantation (HCT). High mobility group box 1 protein (HMBG1) is a pleiotropic cytokine that functions as a pro-inflammatory signal, important for the activation of antigen presenting cells (APCs) and propagation of inflammation. HMGB1 is implicated in the pathophysiology of a variety of inflammatory diseases, and we have recently found the variation in the HMGB1 gene to be associated with mortality in patients with systemic inflammatory response syndrome. To assess the impact of the genetic variation in HMGB1 on outcome after allogeneic HCT, we genotyped 276 and 146 patient/donor pairs treated with allogeneic HCT for hematologic malignancies following myeloablative (MA) or nonmyeloablative (NMA) conditioning. Associations between genotypes and outcome were only observed in the cohort treated with MA conditioning. Patient homozygosity or heterozygosity for the-1377delA minor allele was associated with increased risk of relapse (hazard ratio [HR] 2.11, P = .02) and increased relapse related mortality (RRM) (P = .03). Furthermore, patient homozygosity for the 3814C > G minor allele was associated with increased overall survival (OS; HR 0.13, P = .04), progression free survival (PFS; HR 0.30, P = .05) and decreased probability of RRM (P = .03). Patient carriage of the 2351insT minor allele reduced the risk of grade II to IV acute graft-versus-host disease (aGVHD) (HR 0.60, P = .01), whereas donor homozygosity was associated with chronic GVHD (cGVHD) (HR 1.54, P = .01). Our findings suggest that the inherited variation in HMGB1 is associated with outcome after allogeneic HCT following MA conditioning. None of the polymorphisms were associated with treatment-related mortality (TRM).

AB - Several studies have demonstrated that genetic variation in cytokine genes can modulate the immune reactions after allogeneic hematopoietic cell transplantation (HCT). High mobility group box 1 protein (HMBG1) is a pleiotropic cytokine that functions as a pro-inflammatory signal, important for the activation of antigen presenting cells (APCs) and propagation of inflammation. HMGB1 is implicated in the pathophysiology of a variety of inflammatory diseases, and we have recently found the variation in the HMGB1 gene to be associated with mortality in patients with systemic inflammatory response syndrome. To assess the impact of the genetic variation in HMGB1 on outcome after allogeneic HCT, we genotyped 276 and 146 patient/donor pairs treated with allogeneic HCT for hematologic malignancies following myeloablative (MA) or nonmyeloablative (NMA) conditioning. Associations between genotypes and outcome were only observed in the cohort treated with MA conditioning. Patient homozygosity or heterozygosity for the-1377delA minor allele was associated with increased risk of relapse (hazard ratio [HR] 2.11, P = .02) and increased relapse related mortality (RRM) (P = .03). Furthermore, patient homozygosity for the 3814C > G minor allele was associated with increased overall survival (OS; HR 0.13, P = .04), progression free survival (PFS; HR 0.30, P = .05) and decreased probability of RRM (P = .03). Patient carriage of the 2351insT minor allele reduced the risk of grade II to IV acute graft-versus-host disease (aGVHD) (HR 0.60, P = .01), whereas donor homozygosity was associated with chronic GVHD (cGVHD) (HR 1.54, P = .01). Our findings suggest that the inherited variation in HMGB1 is associated with outcome after allogeneic HCT following MA conditioning. None of the polymorphisms were associated with treatment-related mortality (TRM).

U2 - 10.1016/j.bbmt.2009.10.002

DO - 10.1016/j.bbmt.2009.10.002

M3 - Journal article

C2 - 19819342

VL - 16

SP - 239

EP - 252

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 2

ER -

ID: 19440188